Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study

被引：12

作者：

Andersson, H ^{[1
]}

Horvath, G ^{[1
]}

Mellqvist, L ^{[1
]}

Westberg, R ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB,CLIN ONCOL RES DEPT,STOCKHOLM,SWEDEN

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 1997年 / 7卷 / 04期

关键词：

chemotherapy; ovarian cancer; Taxol; weekly;

D O I：

10.1046/j.1525-1438.1997.00449.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this pilot study, 42 patients with advanced ovarian carcinoma were treated with Taxol weekly instead of every 3 weeks. The initial dose was 67 mg m(-2). The clinical response rate was 29%. The response rate was 22% for patients with platinum-resistant tumors compared to 42% for patients with platinum-sensitive tumors. This difference was not statistically significant. The median progression free survival was 110 days and the median overall survival 341 days. The toxicity was acceptable and probably less pronounced than with the standard triweekly schedule. A randomized multicenter study comparing these two treatment schedules is presently under way in Scandinavia.

引用

页码：262 / 266

页数：5

共 28 条

[1] DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP [J].

AAMDAL, S ;

WOLFF, I ;

KAPLAN, S ;

PARIDAENS, R ;

KERGER, J ;

SCHACHTER, J ;

WANDERS, J ;

FRANKLIN, HR ;

VERWEIJ, J .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1061-1064

[2]

AKERLEY W, 1995, P AM SOC CLIN ONCOL, V14, P94

[3]

CAVALETTI G, 1995, CANCER, V75, P1141, DOI 10.1002/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO

[4]

2-U

[5]

CHOY H, 1995, SEMIN ONCOL, V22, P55

[6] ONYCHOLYSIS ASSOCIATED WITH CYTO-TOXIC DRUGS [J].

CUNNINGHAM, D ;

GILCHRIST, NL ;

FORREST, GJ ;

SOUKOP, M .

BRITISH MEDICAL JOURNAL, 1985, 290 (6469) :675-676

[7] ONYCHOLYSIS IN DOXORUBICIN-TREATED PATIENTS [J].

CURRAN, CF .

ARCHIVES OF DERMATOLOGY, 1990, 126 (09) :1244-1244

[8] PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA [J].

EINZIG, AI ;

WIERNIK, PH ;

SASLOFF, J ;

RUNOWICZ, CD ;

GOLDBERG, GL .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1748-1753

[9] EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].

EISENHAUER, EA ;

HUININK, WWT ;

SWENERTON, KD ;

GIANNI, L ;

MYLES, J ;

VANDERBURG, MEL ;

KERR, I ;

VERMORKEN, JB ;

BUSER, K ;

COLOMBO, N ;

BACON, M ;

SANTABARBARA, P ;

ONETTO, N ;

WINOGRAD, B ;

CANETTA, R .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666

[10]

FENELLY D, 1995, P AM SOC CLIN ONCOL, V14, P61

← 1 2 3 →